(Q35964412)

11 August 2017

1 reference

title

Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials (English)

1 reference

11 August 2017

1 reference

Rudolph M Navari

1

1 reference

11 August 2017

publication date

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

22

1 reference

11 August 2017

issue

4

1 reference

11 August 2017

page(s)

569-576

1 reference

On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027137

Quality of life studies in chemotherapy-induced emesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027137

Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban).

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027137

Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027137

Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027137

The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027137

The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027137

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027137

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027137

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027137

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027137

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027137

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027137

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027137

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027137

21 January 2018

Identifiers

DOI

10.1081/CNV-200027137

1 reference

11 August 2017

1 reference